Ouabain-specific monoclonal antibodies

Details Ouabain-specific monoclonal antibodies Ouabain-specific monoclonal antibodies

1999-10-05

2008-03-25

Ungar, Susan (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S350000, C530S388100, C530S388250, C530S388850

Reexamination Certificate

active

07348412

ABSTRACT:
The invention relates to a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain, wherein the antibody or antigen binding fragment does not crossreact with digoxin. Preferably the anti-ouabain monoclonal antibody can bind ouabain with an affinity of at least about 10−7M, preferably 10−8M, and more preferably 10−9M. The invention also relates to diagnostic and therapeutic uses of the monoclonal antibodies described herein.

REFERENCES:
patent: 5164296 (1992-11-01), Blaustein et al.
patent: 5695756 (1997-12-01), Blaustein et al.
patent: 5716937 (1998-02-01), Haupert, Jr.
http://thefreedictionary.com/pharmaceutical.
Stites ed al (Basic and Clinical Immunology, 7th Edition, 1976, Prentice Hall, London, p. 244).
Lin, M., et al., “Detection of Endogenous Digitalis-like Immunoreactive Factors in Human Blood,”Proceedings of the National Science Council, ROC, Part B: Life Sciences, 22(3)129-135 (1998).
Parhami-Seren, B., et al., “Monoclonal Antibodies that Distinguish Between Two Related Digitalis Glycosides, Ouabain and Digoxin”,J. Immunol., 163(8):4360-4366 (1999).
Manunta, P., et al., “Left Ventricular Mass, Stroke Volume, and Ouabain-Like Factor in Essential Hypertension”,Hypertension, 34(3):450-456 (1999).
Ferrandi, M., et al., “Ouabain-Like Factor Quantification in Mammalian Tissues and Plasmas”,Hypertension, 30:886-896 (1997).
Parhami-Seren, B., “Contribution of Heavy Chain Junctional Amino Acid Diversity to Antibody Affinity Amongp-Azophenylarsonate-Specific Antibodies”,J. Immunol., 157(5):2066-2072 (1996).
Blaustein, M.P., “Endogenous ouabain: Role in the pathogenesis of hypertension”,Kidney Int'l., 49:1748-1753 (1996).
Jeffrey, P.D., “Structure and Specificity of the Anti-Digoxin Antibody 40-50”,J. Mol. Biol., 248:344-360 (1995).
Tymiak, A.A., et al., “Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus”,Proc. Natl. Acad. Sci. USA, 90:8189-8193 (1993).
Schildbach, J.F., et al., “Heavy Chain Position 50 Is a Determinant of Affinity and Specificity for the Anti-digoxin Antibody 26-10”,J. Biol. Chem., 268(29):21739-21747 (1993).
Ludens, J.H., et al., “Digitalis-Like Factor and Ouabain-Like Compound in Plasma of Volume-Expanded Dogs”,J. Cardiovas. Pharm., 22(Suppl. 2):S38-S41 (1993).
Goto, A., et al., “Physiology and Pharmacology of Endogenous Digitalis-like Factors”,Pharm. Reviews, 44:377-399 (1992).
Terano, Y., et al., “Production and Charaterization of Antibodies to Ouabain”,Jpn. J. Med. Sci. Biol., 44:123-139 (1991).
Schildbach, J.F., et al., “Altered Hapten Recognition by Two Anti-digoxin Hybridoma Variants Due to Variable Region Point Mutations”,J. Biol. Chem., 266(7):4640-4647 (1991).
Hamlyn, J.M., et al., “Identification and characterization of a ouabain-like compound from human plasma”,Proc. Natl. Acad. Sci. USA, 88:6259-6263 (1991).
Shaikh, I.M., et al., “Isolation of Digoxin-like Immunoreactive Factors from Mammalian Adrenal Cortex”,J. Biol. Chem., 266(21):13672-13678.
Panka, D.J., et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies”,Proc. Natl. Acad. Sci. USA, 85:3080-3-84 (1988).
Haupert, Jr., G., et al., “Hypothalamic sodium-transport inhibitor is a high-affinity reversible inhibitor of Na+-K+-ATPase”,Am. J. Physiol., 247:F919-F924 (1984).
Mudgett-Hunter, M., et al., “Binding and Structural Diversity Among High-Affinity Monoclonal Anti-digoxin Antibodies” ,Mol. Immunol., 22(4):477-488 (1985).
Mudgett-Hunter, M., et al., “High-Affinity Monoclonal Antibodies to the Cardiac Glycoside, Digoxin”,J. Immunol., 129(3):1165-1172 (1982).
Haupert, Jr., G. and Sancho, J.M., “Sodium transport inhibitor from bovine hypothalamus”,Proc. Natl. Acad. Sci. USA, 76(9):4658-4660 (1979).
Smith, T.W., et al., “Characterization of Antibodies of High Affinity and Specificity for the Digitalis Glycoside Digoxin”,Biochem., 9:331-337 (1970).
Jacobs, W.A. and Bigelow, N.M., “Ouabain or g-Strophanthin”,J. Biol. Chem., 96:647-658 (1932).

Affiliated with

Also associated with

Rating

Ouabain-specific monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ouabain-specific monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ouabain-specific monoclonal antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3962326